Literature DB >> 24334687

Large-scale prospective T cell function assays in shipped, unfrozen blood samples: experiences from the multicenter TRIGR trial.

David Hadley1, Roy K Cheung, Dorothy J Becker, Rose Girgis, Jerry P Palmer, David Cuthbertson, Jeffrey P Krischer, Hans-Michael Dosch.   

Abstract

Broad consensus assigns T lymphocytes fundamental roles in inflammatory, infectious, and autoimmune diseases. However, clinical investigations have lacked fully characterized and validated procedures, equivalent to those of widely practiced biochemical tests with established clinical roles, for measuring core T cell functions. The Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR) type 1 diabetes prevention trial used consecutive measurements of T cell proliferative responses in prospectively collected fresh heparinized blood samples shipped by courier within North America. In this article, we report on the quality control implications of this simple and pragmatic shipping practice and the interpretation of positive- and negative-control analytes in our assay. We used polyclonal and postvaccination responses in 4,919 samples to analyze the development of T cell immunocompetence. We have found that the vast majority of the samples were viable up to 3 days from the blood draw, yet meaningful responses were found in a proportion of those with longer travel times. Furthermore, the shipping time of uncooled samples significantly decreased both the viabilities of the samples and the unstimulated cell counts in the viable samples. Also, subject age was significantly associated with the number of unstimulated cells and T cell proliferation to positive activators. Finally, we observed a pattern of statistically significant increases in T cell responses to tetanus toxin around the timing of infant vaccinations. This assay platform and shipping protocol satisfy the criteria for robust and reproducible long-term measurements of human T cell function, comparable to those of established blood biochemical tests. We present a stable technology for prospective disease-relevant T cell analysis in immunological diseases, vaccination medicine, and measurement of herd immunity.

Entities:  

Mesh:

Year:  2013        PMID: 24334687      PMCID: PMC3910927          DOI: 10.1128/CVI.00516-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

1.  Ontogeny of immunity in humans.

Authors:  D P Stites; J Caldwell; M C Carr; H H Fudenberg
Journal:  Clin Immunol Immunopathol       Date:  1975-11

2.  Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.

Authors:  Vicki Seyfert-Margolis; Trang D Gisler; Adam L Asare; Richard S Wang; H Michael Dosch; Barbara Brooks-Worrell; George S Eisenbarth; Jerry P Palmer; Carla J Greenbaum; Stephen E Gitelman; Gerald T Nepom; Jeffrey A Bluestone; Kevan C Herold
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

3.  Persistent T cell anergy in human type 1 diabetes.

Authors:  H Dosch; R K Cheung; W Karges; M Pietropaolo; D J Becker
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

4.  A Wilcoxon-type test for trend.

Authors:  J Cuzick
Journal:  Stat Med       Date:  1985 Jan-Mar       Impact factor: 2.373

5.  Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays.

Authors:  B O Roep; M A Atkinson; P M van Endert; P A Gottlieb; S B Wilson; J A Sachs
Journal:  J Autoimmun       Date:  1999-09       Impact factor: 7.094

6.  Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive.

Authors:  Shawn Winer; Hubert Tsui; Ambrose Lau; Aihua Song; Xiaomao Li; Roy K Cheung; Anastazia Sampson; Fatemeh Afifiyan; Alisha Elford; George Jackowski; Dorothy J Becker; Pere Santamaria; Pamela Ohashi; H-Michael Dosch
Journal:  Nat Med       Date:  2003-01-21       Impact factor: 53.440

7.  T cell activation and anergy to islet cell antigen in type I diabetes.

Authors:  I Miyazaki; R K Cheung; R Gaedigk; M F Hui; J Van der Meulen; R V Rajotte; H M Dosch
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

8.  Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

Authors: 
Journal:  Pediatr Diabetes       Date:  2007-06       Impact factor: 4.866

9.  Polyclonal activation of human lymphocytes in vitro-II. Reappraisal of T and B cell-specific mitogens.

Authors:  H M Dosch; R K Schuurman; E W Gelfand
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

10.  T cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years.

Authors:  Frederikke Falkencrone Rönsholt; Sisse Rye Ostrowski; Terese Lea Katzenstein; Henrik Ullum; Jan Gerstoft
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

View more
  2 in total

Review 1.  Biomarkers in type 1 diabetes: application to the clinical trial setting.

Authors:  James E Tooley; Kevan C Herold
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

2.  Neuronal T-cell autoreactivity is amplified in overweight children with new-onset insulin-requiring diabetes.

Authors:  Melissa A Buryk; H-Michael Dosch; Ingrid Libman; Vincent C Arena; Yihe Huang; Roy K Cheung; Massimo Trucco; Massimo Pietropaolo; Dorothy J Becker
Journal:  Diabetes Care       Date:  2014-11-20       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.